Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice

Recurrent locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) is associated with dismal prognosis because of its highly invasive behavior and resistance to conventional intensive chemotherapy. The combination of targeted therapy and conventional chemotherapy has significantl...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 21; no. 20; p. 7621
Main Authors Wang, Hui-Ching, Yeh, Tsung-Jang, Chan, Leong-Perng, Hsu, Chin-Mu, Cho, Shih-Feng
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 15.10.2020
MDPI
Subjects
Animals
Biomarkers
Biomarkers, Tumor - genetics
Biomarkers, Tumor - immunology
Biomarkers, Tumor - metabolism
Cancer therapies
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - immunology
Chemotherapy
Clinical medicine
Clinical trials
Epidermal growth factor
Gene expression
Head & neck cancer
Head and Neck Neoplasms - drug therapy
Head and Neck Neoplasms - genetics
Head and Neck Neoplasms - immunology
Human papillomavirus
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Ligands
Medical prognosis
Metastasis
Mutation Accumulation
Pharmacodynamics
Practice Guidelines as Topic
Regulatory approval
Response rates
Review
T-Lymphocytes - immunology
immune checkpoint inhibitor
head and neck cancer
biomarker
immunotherapy
Online AccessGet full text

Cover

Abstract Recurrent locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) is associated with dismal prognosis because of its highly invasive behavior and resistance to conventional intensive chemotherapy. The combination of targeted therapy and conventional chemotherapy has significantly improved clinical outcomes. In recent years, the development of immunotherapies, such as immune checkpoint inhibitors (ICIs), has further increased treatment responses and prolonged survival. However, the limited response rate, risk of immunotherapy-related adverse effects and high cost of immunotherapy make the identification of predictive markers to optimize treatment efficacy a critical issue. Biomarkers are biological molecules that have been widely utilized to predict treatment response to certain treatments and clinical outcomes or to detect disease. An ideal biomarker should exhibit good predictive ability, which can guide healthcare professionals to achieve optimal treatment goals and bring clinical benefit to patients. In this review, we summarized the results of recent and important studies focused on HNSCC ICI immunotherapy and discussed potential biomarkers including their strengths and limitations, aiming to gain more insight into HNSCC immunotherapy in real world clinical practice.
AbstractList Recurrent locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) is associated with dismal prognosis because of its highly invasive behavior and resistance to conventional intensive chemotherapy. The combination of targeted therapy and conventional chemotherapy has significantly improved clinical outcomes. In recent years, the development of immunotherapies, such as immune checkpoint inhibitors (ICIs), has further increased treatment responses and prolonged survival. However, the limited response rate, risk of immunotherapy-related adverse effects and high cost of immunotherapy make the identification of predictive markers to optimize treatment efficacy a critical issue. Biomarkers are biological molecules that have been widely utilized to predict treatment response to certain treatments and clinical outcomes or to detect disease. An ideal biomarker should exhibit good predictive ability, which can guide healthcare professionals to achieve optimal treatment goals and bring clinical benefit to patients. In this review, we summarized the results of recent and important studies focused on HNSCC ICI immunotherapy and discussed potential biomarkers including their strengths and limitations, aiming to gain more insight into HNSCC immunotherapy in real world clinical practice.Recurrent locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) is associated with dismal prognosis because of its highly invasive behavior and resistance to conventional intensive chemotherapy. The combination of targeted therapy and conventional chemotherapy has significantly improved clinical outcomes. In recent years, the development of immunotherapies, such as immune checkpoint inhibitors (ICIs), has further increased treatment responses and prolonged survival. However, the limited response rate, risk of immunotherapy-related adverse effects and high cost of immunotherapy make the identification of predictive markers to optimize treatment efficacy a critical issue. Biomarkers are biological molecules that have been widely utilized to predict treatment response to certain treatments and clinical outcomes or to detect disease. An ideal biomarker should exhibit good predictive ability, which can guide healthcare professionals to achieve optimal treatment goals and bring clinical benefit to patients. In this review, we summarized the results of recent and important studies focused on HNSCC ICI immunotherapy and discussed potential biomarkers including their strengths and limitations, aiming to gain more insight into HNSCC immunotherapy in real world clinical practice.
Recurrent locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) is associated with dismal prognosis because of its highly invasive behavior and resistance to conventional intensive chemotherapy. The combination of targeted therapy and conventional chemotherapy has significantly improved clinical outcomes. In recent years, the development of immunotherapies, such as immune checkpoint inhibitors (ICIs), has further increased treatment responses and prolonged survival. However, the limited response rate, risk of immunotherapy-related adverse effects and high cost of immunotherapy make the identification of predictive markers to optimize treatment efficacy a critical issue. Biomarkers are biological molecules that have been widely utilized to predict treatment response to certain treatments and clinical outcomes or to detect disease. An ideal biomarker should exhibit good predictive ability, which can guide healthcare professionals to achieve optimal treatment goals and bring clinical benefit to patients. In this review, we summarized the results of recent and important studies focused on HNSCC ICI immunotherapy and discussed potential biomarkers including their strengths and limitations, aiming to gain more insight into HNSCC immunotherapy in real world clinical practice.
Author Wang, Hui-Ching
Chan, Leong-Perng
Hsu, Chin-Mu
Cho, Shih-Feng
Yeh, Tsung-Jang
AuthorAffiliation 1 Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan; joellewang66@gmail.com (H.-C.W.); aw7719@gmail.com (T.-J.Y.); 930607@kmuh.org.tw (L.-P.C.)
2 Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan; e12013@gmail.com
4 Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
3 Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 807, Taiwan
5 Department of Otolaryngology-Head and Neck Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan
AuthorAffiliation_xml – name: 2 Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan; e12013@gmail.com
– name: 1 Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan; joellewang66@gmail.com (H.-C.W.); aw7719@gmail.com (T.-J.Y.); 930607@kmuh.org.tw (L.-P.C.)
– name: 5 Department of Otolaryngology-Head and Neck Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan
– name: 3 Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 807, Taiwan
– name: 4 Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
Author_xml – sequence: 1
  givenname: Hui-Ching
  orcidid: 0000-0002-8232-0387
  surname: Wang
  fullname: Wang, Hui-Ching
– sequence: 2
  givenname: Tsung-Jang
  orcidid: 0000-0003-1634-2219
  surname: Yeh
  fullname: Yeh, Tsung-Jang
– sequence: 3
  givenname: Leong-Perng
  surname: Chan
  fullname: Chan, Leong-Perng
– sequence: 4
  givenname: Chin-Mu
  orcidid: 0000-0002-3604-6022
  surname: Hsu
  fullname: Hsu, Chin-Mu
– sequence: 5
  givenname: Shih-Feng
  surname: Cho
  fullname: Cho, Shih-Feng
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33076306$$D View this record in MEDLINE/PubMed
BookMark eNptkk1v1DAQhi1URD_gxhlZ4sKhC7YTx8kFCaKWrlQBgiKO1sSZsN469tZOUPkx_Fe89ENLxWns8TOv5vXMIdnzwSMhzzl7XRQNe2PXYxJcMFUJ_ogc8FKIBWOV2ts575PDlNaMiULI5gnZL4qMF6w6IL9PrjcuRJhs8DQM9BQh2c4hXY7j7JG-t2GEeIkx0SHEu2y7QnO5CdZPdOlXtrNTyID19Ayhp-B7-jED9OvVDGOYE23ROdpCNNZnOXoREaYRc3Uu-YLg6PcQXU9bZ701-fo5gpmswafk8QAu4bPbeES-nZ5ctGeL808flu2784UpuZgWcpCV6ZhSnSlVDqWQHJUQrFasG4a6KZEr1ciGoWSNgh5gQFX2vB5QSuDFEXl7o7uZuxF7k1uL4PQm2mz-lw5g9b8v3q70j_BTK1k3rK6zwKtbgRiuZkyTHm0y2TV4zB-gRSmFZFXNq4y-fICuwxx9tqeFLOtqO6Kt4Ivdju5buZtcBo5vABNDShGHe4QzvV0MvbsYGRcPcGOnv1PPfqz7f9EfAne9pQ
CitedBy_id crossref_primary_10_3389_fmed_2022_827297
crossref_primary_10_3389_fonc_2022_800315
crossref_primary_10_37349_ei_2021_00013
crossref_primary_10_1001_jamaoto_2021_2191
crossref_primary_10_1042_BSR20203829
crossref_primary_10_1515_oncologie_2024_0086
crossref_primary_10_3390_cancers13071714
crossref_primary_10_5306_wjco_v13_i5_388
crossref_primary_10_7717_peerj_16014
crossref_primary_10_1155_2022_8433489
crossref_primary_10_3892_or_2024_8800
crossref_primary_10_3390_biomedicines11123113
crossref_primary_10_3390_cells13181557
Cites_doi 10.1186/s12967-016-1029-z
10.1155/2015/368736
10.1158/1078-0432.CCR-13-1101
10.1016/j.oraloncology.2018.04.009
10.1016/S0140-6736(18)31999-8
10.3390/ijms19040936
10.1056/NEJMra0707975
10.1016/j.molmed.2017.02.007
10.1056/NEJMoa1503093
10.1158/2159-8290.CD-18-1522
10.1038/s12276-018-0191-1
10.1038/s41388-020-1327-z
10.1158/1538-7445.AM2018-LB-339
10.1200/JCO.2012.43.6097
10.1038/s41388-018-0657-6
10.1158/2326-6066.CIR-15-0097
10.1016/j.cell.2017.07.008
10.1016/S0140-6736(19)32591-7
10.1038/s41598-020-63055-y
10.1002/hed.25932
10.1038/ncomms10501
10.1139/cjm-2016-0603
10.1093/annonc/mdu271
10.1038/s41598-017-16918-w
10.1056/NEJMoa1712126
10.1056/NEJMoa1500596
10.1038/srep24927
10.1038/d41586-020-00844-5
10.3390/ijms20112699
10.1016/j.ejca.2018.11.015
10.1016/j.radonc.2011.05.036
10.1016/j.oraloncology.2019.104558
10.2147/CMAR.S115761
10.1371/journal.pone.0093210
10.14740/jocmr3750
10.1200/JCO.2020.38.15_suppl.6511
10.1158/0008-5472.CAN-16-3453
10.1016/j.immuni.2016.05.001
10.1056/NEJMc1713444
10.1016/j.cellimm.2013.04.005
10.1093/annonc/mdz116
10.1016/j.ejca.2017.12.016
10.1007/s12032-018-1241-1
10.1126/science.aar3593
10.1056/NEJMoa1602252
10.1016/j.oraloncology.2017.09.002
10.1093/jnci/djy060
10.1136/esmoopen-2017-000257
10.1002/hed.25744
10.1002/hed.23126
10.1126/science.aan6733
10.1038/s41598-018-19245-w
10.1158/1078-0432.1160.11.3
10.1172/JCI80445
10.1016/j.ejca.2018.12.029
10.1016/j.suronc.2018.04.007
10.1056/NEJMoa1801946
10.1186/1471-2180-12-144
10.1038/s41416-020-0984-6
10.1111/jop.13075
10.1038/bjc.2013.645
10.1126/science.aaf1490
10.1016/j.it.2020.06.010
10.1016/j.oraloncology.2017.09.012
10.1158/1538-7445.AM2017-CT022
10.1158/2159-8290.CD-13-0103
10.1200/JCO.2016.68.1478
10.1080/2162402X.2018.1535293
10.4161/21624011.2014.965570
10.1001/jamaoncol.2019.2311
10.1172/jci.insight.98811
10.1186/s40425-018-0442-7
10.1002/hed.21140
10.1016/j.oraloncology.2018.04.001
10.3727/096504005776404599
10.1177/1535370217750088
10.3389/fonc.2019.01084
10.1038/srep36956
10.1016/j.humpath.2018.07.012
10.1038/s41551-018-0305-z
10.1016/j.humpath.2015.09.003
10.1016/S1470-2045(16)30066-3
10.1038/s41571-019-0218-0
10.1038/srep31726
10.1038/cgt.2016.63
10.3747/co.25.4031
10.1038/nrc3239
10.1038/s41379-018-0071-1
10.1093/jnci/djn011
10.1038/nrgastro.2013.238
10.1093/annonc/mdx206
10.1038/nature14129
10.1126/science.1129139
10.1016/j.oraloncology.2020.104638
10.1158/1055-9965.EPI-10-1262
10.1038/s41598-019-49771-0
10.1200/JCO.2016.70.1524
10.3390/cancers11040540
10.1016/j.oraloncology.2018.04.008
10.1093/annonc/mdy507
10.1038/s41598-017-09786-x
10.1093/annonc/mdz108
10.1016/S1470-2045(17)30421-7
10.1186/s40425-019-0662-5
10.1038/nrc.2017.13
10.1172/jci.insight.89829
10.1038/nature06913
10.1016/j.celrep.2014.05.012
10.1001/jamaoncol.2015.4685
10.1186/s40425-019-0726-6
10.1038/s41416-019-0616-1
10.1158/1078-0432.CCR-15-2412
10.1056/NEJMoa0802656
10.1126/science.aaa8172
10.1038/nature25015
10.1016/j.lungcan.2018.04.001
10.1038/nri.2018.4
10.1093/annonc/mdy411
10.1016/j.oraloncology.2019.07.020
10.1016/j.cell.2018.11.021
10.1038/bjc.2013.576
10.18632/oncotarget.17901
10.1200/JCO.2019.37.15_suppl.6002
10.1038/s43018-020-0096-5
10.1126/science.aan4236
10.1002/cncr.32190
10.1200/JCO.2006.07.2587
10.1056/NEJMoa1801005
10.1056/NEJMoa1606774
10.1158/2159-8290.CD-18-0367
10.1158/0008-5472.CAN-16-3556
10.1038/bjc.2017.434
10.1016/j.oraloncology.2013.09.009
10.1158/1078-0432.CCR-14-1905
10.18632/oncotarget.17547
10.1158/1078-0432.CCR-16-1821
ContentType Journal Article
Copyright 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2020 by the authors. 2020
Copyright_xml – notice: 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2020 by the authors. 2020
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
M0S
M1P
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
Q9U
7X8
5PM
DOI 10.3390/ijms21207621
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database

MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1422-0067
ExternalDocumentID PMC7589088
33076306
10_3390_ijms21207621
Genre Journal Article
Review
GroupedDBID ---
29J
2WC
53G
5GY
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
8G5
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
AEAQA
AENEX
AFKRA
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
CS3
D1I
DIK
DU5
DWQXO
E3Z
EBD
EBS
EJD
ESX
F5P
FRP
FYUFA
GNUQQ
GUQSH
GX1
HH5
HMCUK
HYE
IAO
IHR
ITC
KQ8
LK8
M1P
M2O
M48
MODMG
O5R
O5S
OK1
OVT
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RPM
TR2
TUS
UKHRP
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
3V.
7XB
8FK
K9.
MBDVC
PKEHL
PQEST
PQUKI
Q9U
7X8
5PM
ID FETCH-LOGICAL-c412t-5f56cb077bc470774251e7220870bff894e1779590e5097adaafe74d18fe55a13
IEDL.DBID M48
ISSN 1422-0067
1661-6596
IngestDate Thu Aug 21 18:25:48 EDT 2025
Fri Jul 11 16:06:39 EDT 2025
Fri Jul 25 20:15:54 EDT 2025
Mon Jul 21 05:51:41 EDT 2025
Tue Jul 01 04:15:43 EDT 2025
Thu Apr 24 23:11:48 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 20
Keywords immune checkpoint inhibitor
head and neck cancer
biomarker
immunotherapy
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c412t-5f56cb077bc470774251e7220870bff894e1779590e5097adaafe74d18fe55a13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-8232-0387
0000-0003-1634-2219
0000-0002-3604-6022
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/ijms21207621
PMID 33076306
PQID 2548632598
PQPubID 2032341
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7589088
proquest_miscellaneous_2452506816
proquest_journals_2548632598
pubmed_primary_33076306
crossref_primary_10_3390_ijms21207621
crossref_citationtrail_10_3390_ijms21207621
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20201015
PublicationDateYYYYMMDD 2020-10-15
PublicationDate_xml – month: 10
  year: 2020
  text: 20201015
  day: 15
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle International journal of molecular sciences
PublicationTitleAlternate Int J Mol Sci
PublicationYear 2020
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Martins (ref_16) 2019; 16
ref_136
Yuki (ref_139) 2020; 41
Robert (ref_8) 2015; 372
Bratman (ref_113) 2020; 1
Desrichard (ref_102) 2018; 110
ref_132
Sunshine (ref_64) 2017; 23
Zhang (ref_28) 2016; 6
Cohen (ref_62) 2019; 7
Wang (ref_119) 2019; 41
Lui (ref_56) 2013; 3
Mattox (ref_61) 2017; 77
Blanchard (ref_3) 2011; 100
Faden (ref_77) 2017; 74
Yu (ref_30) 2005; 11
Faden (ref_78) 2019; 96
Zhang (ref_90) 2018; 82
Seiwert (ref_100) 2016; 17
Liu (ref_115) 2020; 43
Ishiguro (ref_38) 2003; 23
Yu (ref_144) 2018; 2
Bauml (ref_73) 2017; 35
ref_129
Gandhi (ref_10) 2018; 378
Scognamiglio (ref_140) 2019; 121
Hayes (ref_35) 2011; 31
Greenhill (ref_127) 2014; 11
Harrington (ref_12) 2017; 18
ref_122
ref_121
Guigay (ref_6) 2019; 37
Sharma (ref_13) 2015; 348
Galon (ref_87) 2016; 14
Zandberg (ref_53) 2019; 107
Leduc (ref_57) 2018; 3
Dutta (ref_137) 2017; 23
Rodrigo (ref_36) 2000; 6
Thompson (ref_58) 2016; 47
Lechner (ref_69) 2019; 8
Guibert (ref_123) 2018; 120
Li (ref_85) 2020; 38
Luchini (ref_108) 2019; 30
Tardy (ref_107) 2018; 80
Albers (ref_27) 2017; 7
Ferris (ref_54) 2018; 81
Partlova (ref_67) 2015; 4
Strati (ref_120) 2017; 28
Koppel (ref_63) 2018; 31
Motzer (ref_49) 2018; 378
Hooper (ref_133) 2009; 31
Driehuis (ref_141) 2019; 9
Wang (ref_68) 2019; 9
Lechner (ref_91) 2017; 8
Reck (ref_52) 2016; 375
Colevas (ref_74) 2018; 29
Hsieh (ref_21) 2019; 41
Martens (ref_106) 2016; 22
Galon (ref_88) 2006; 313
Misawa (ref_112) 2020; 39
Semrau (ref_24) 2013; 35
ref_83
Dhar (ref_125) 2018; 8
Ngamphaiboon (ref_45) 2019; 36
Darvin (ref_14) 2018; 50
Sawyers (ref_19) 2008; 452
Dubot (ref_37) 2018; 91
ref_142
Le (ref_104) 2017; 357
Ionescu (ref_65) 2018; 25
ref_84
Oliva (ref_42) 2019; 30
Hellmann (ref_81) 2018; 378
Economopoulou (ref_111) 2017; 74
Haddad (ref_97) 2019; 125
Segal (ref_50) 2019; 109
Bauman (ref_34) 2013; 109
Ferris (ref_103) 2013; 49
Tada (ref_110) 2020; 102
Jamieson (ref_98) 2017; 24
(ref_116) 2020; 579
Pardoll (ref_43) 2012; 12
ref_55
Cannataro (ref_76) 2019; 38
Califf (ref_18) 2018; 243
Koyama (ref_93) 2016; 7
Zhang (ref_44) 2018; 553
Gallo (ref_32) 1996; 2
Verma (ref_15) 2018; 6
Shin (ref_134) 2017; 7
Neal (ref_138) 2018; 175
Young (ref_25) 2011; 20
Anderson (ref_92) 2016; 44
Hernandez (ref_101) 2013; 282
Denaro (ref_2) 2017; 9
Cohen (ref_51) 2019; 393
Xun (ref_114) 2020; 104
Ferris (ref_11) 2016; 375
Henderson (ref_75) 2014; 7
Prat (ref_99) 2017; 77
Ferris (ref_135) 2017; 77
Goossens (ref_20) 2015; 4
Donnem (ref_89) 2015; 21
Vermorken (ref_5) 2008; 359
Hansen (ref_48) 2016; 2
Tinhofer (ref_117) 2014; 25
Grobe (ref_118) 2014; 20
Falaschini (ref_33) 2005; 15
Ang (ref_23) 2002; 62
Nicolazzo (ref_124) 2016; 6
Chauvin (ref_95) 2015; 125
Burtness (ref_9) 2019; 394
Takamori (ref_59) 2017; 37
McGranahan (ref_79) 2016; 351
Haddad (ref_1) 2008; 359
Rasmussen (ref_26) 2018; 81
Le (ref_105) 2015; 372
ref_31
Roy (ref_126) 2017; 17
ref_39
Jie (ref_60) 2013; 109
Matamoros (ref_131) 2017; 63
Wang (ref_66) 2019; 9
Chow (ref_72) 2016; 34
Fakhry (ref_29) 2008; 100
Yu (ref_41) 2017; 170
Yarchoan (ref_80) 2017; 377
Forastiere (ref_4) 2013; 31
Nelson (ref_40) 2015; 2015
Bajwa (ref_17) 2019; 11
Okada (ref_47) 2018; 27
Seiwert (ref_82) 2018; 78
Kim (ref_70) 2016; 6
Thommen (ref_94) 2015; 3
Kroemer (ref_128) 2018; 18
Muller (ref_46) 2017; 8
Gopalakrishnan (ref_130) 2018; 359
Chung (ref_22) 2006; 24
Mandal (ref_71) 2016; 1
Hladikova (ref_86) 2019; 7
Jenkins (ref_96) 2018; 118
Trebeschi (ref_143) 2019; 30
Wei (ref_7) 2018; 8
Zavridou (ref_109) 2020; 10
References_xml – volume: 14
  start-page: 273
  year: 2016
  ident: ref_87
  article-title: Immunoscore and Immunoprofiling in cancer: An update from the melanoma and immunotherapy bridge 2015
  publication-title: J. Transl. Med.
  doi: 10.1186/s12967-016-1029-z
– volume: 2015
  start-page: 368736
  year: 2015
  ident: ref_40
  article-title: Harnessing the Microbiome to Enhance Cancer Immunotherapy
  publication-title: J. Immunol. Res.
  doi: 10.1155/2015/368736
– volume: 20
  start-page: 425
  year: 2014
  ident: ref_118
  article-title: Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-13-1101
– volume: 81
  start-page: 52
  year: 2018
  ident: ref_26
  article-title: A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients
  publication-title: Oral Oncol.
  doi: 10.1016/j.oraloncology.2018.04.009
– volume: 393
  start-page: 156
  year: 2019
  ident: ref_51
  article-title: Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(18)31999-8
– ident: ref_136
  doi: 10.3390/ijms19040936
– volume: 359
  start-page: 1143
  year: 2008
  ident: ref_1
  article-title: Recent advances in head and neck cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMra0707975
– volume: 37
  start-page: 4223
  year: 2017
  ident: ref_59
  article-title: Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer
  publication-title: Anticancer Res.
– volume: 23
  start-page: 393
  year: 2017
  ident: ref_137
  article-title: Disease Modeling in Stem Cell-Derived 3D Organoid Systems
  publication-title: Trends Mol. Med.
  doi: 10.1016/j.molmed.2017.02.007
– volume: 372
  start-page: 2521
  year: 2015
  ident: ref_8
  article-title: Pembrolizumab versus Ipilimumab in Advanced Melanoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1503093
– volume: 9
  start-page: 852
  year: 2019
  ident: ref_141
  article-title: Oral mucosal organoids as a potential platform for personalized cancer therapy
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-1522
– volume: 50
  start-page: 165
  year: 2018
  ident: ref_14
  article-title: Immune checkpoint inhibitors: Recent progress and potential biomarkers
  publication-title: Exp. Mol. Med.
  doi: 10.1038/s12276-018-0191-1
– volume: 39
  start-page: 4741
  year: 2020
  ident: ref_112
  article-title: Identification of novel methylation markers in HPV-associated oropharyngeal cancer: Genome-wide discovery, tissue verification and validation testing in ctDNA
  publication-title: Oncogene
  doi: 10.1038/s41388-020-1327-z
– volume: 78
  start-page: LB-339
  year: 2018
  ident: ref_82
  article-title: Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.AM2018-LB-339
– volume: 31
  start-page: 845
  year: 2013
  ident: ref_4
  article-title: Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2012.43.6097
– volume: 38
  start-page: 3475
  year: 2019
  ident: ref_76
  article-title: APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0657-6
– volume: 3
  start-page: 1344
  year: 2015
  ident: ref_94
  article-title: Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-15-0097
– volume: 170
  start-page: 548
  year: 2017
  ident: ref_41
  article-title: Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
  publication-title: Cell
  doi: 10.1016/j.cell.2017.07.008
– volume: 394
  start-page: 1915
  year: 2019
  ident: ref_9
  article-title: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(19)32591-7
– volume: 10
  start-page: 6551
  year: 2020
  ident: ref_109
  article-title: Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-63055-y
– volume: 41
  start-page: 19
  year: 2019
  ident: ref_21
  article-title: Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy
  publication-title: Head Neck
  doi: 10.1002/hed.25932
– volume: 7
  start-page: 10501
  year: 2016
  ident: ref_93
  article-title: Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms10501
– volume: 63
  start-page: 475
  year: 2017
  ident: ref_131
  article-title: The oral cavity microbiota: Between health, oral disease, and cancers of the aerodigestive tract
  publication-title: Can. J. Microbiol.
  doi: 10.1139/cjm-2016-0603
– volume: 25
  start-page: 2042
  year: 2014
  ident: ref_117
  article-title: Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdu271
– volume: 7
  start-page: 16715
  year: 2017
  ident: ref_27
  article-title: Meta analysis: HPV and p16 pattern determines survival in patients with HNSCC and identifies potential new biologic subtype
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-16918-w
– volume: 378
  start-page: 1277
  year: 2018
  ident: ref_49
  article-title: Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1712126
– volume: 372
  start-page: 2509
  year: 2015
  ident: ref_105
  article-title: PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1500596
– volume: 6
  start-page: 24927
  year: 2016
  ident: ref_28
  article-title: Integrative Genomics and Transcriptomics Analysis Reveals Potential Mechanisms for Favorable Prognosis of Patients with HPV-Positive Head and Neck Carcinomas
  publication-title: Sci. Rep.
  doi: 10.1038/srep24927
– volume: 31
  start-page: 4135
  year: 2011
  ident: ref_35
  article-title: ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation
  publication-title: Anticancer Res.
– volume: 579
  start-page: S9
  year: 2020
  ident: ref_116
  article-title: The future of liquid biopsy
  publication-title: Nature
  doi: 10.1038/d41586-020-00844-5
– ident: ref_129
  doi: 10.3390/ijms20112699
– volume: 107
  start-page: 142
  year: 2019
  ident: ref_53
  article-title: Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with >/=25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2018.11.015
– volume: 100
  start-page: 33
  year: 2011
  ident: ref_3
  article-title: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site
  publication-title: Radiother. Oncol.
  doi: 10.1016/j.radonc.2011.05.036
– volume: 62
  start-page: 7350
  year: 2002
  ident: ref_23
  article-title: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma
  publication-title: Cancer Res.
– volume: 102
  start-page: 104558
  year: 2020
  ident: ref_110
  article-title: Molecular profiling of circulating tumor cells predicts clinical outcome in head and neck squamous cell carcinoma
  publication-title: Oral Oncol.
  doi: 10.1016/j.oraloncology.2019.104558
– volume: 9
  start-page: 363
  year: 2017
  ident: ref_2
  article-title: Head and neck cancer: Improving outcomes with a multidisciplinary approach
  publication-title: Cancer Manag. Res.
  doi: 10.2147/CMAR.S115761
– ident: ref_31
  doi: 10.1371/journal.pone.0093210
– volume: 11
  start-page: 225
  year: 2019
  ident: ref_17
  article-title: Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study
  publication-title: J. Clin. Med. Res.
  doi: 10.14740/jocmr3750
– volume: 38
  start-page: 6511
  year: 2020
  ident: ref_85
  article-title: Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2020.38.15_suppl.6511
– volume: 4
  start-page: 256
  year: 2015
  ident: ref_20
  article-title: Cancer biomarker discovery and validation
  publication-title: Transl. Cancer Res.
– volume: 77
  start-page: 6365
  year: 2017
  ident: ref_61
  article-title: PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4(+) TILs in the Presence of PD-L1(+) TAMs
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-3453
– volume: 44
  start-page: 989
  year: 2016
  ident: ref_92
  article-title: Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.05.001
– volume: 377
  start-page: 2500
  year: 2017
  ident: ref_80
  article-title: Tumor Mutational Burden and Response Rate to PD-1 Inhibition
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc1713444
– volume: 282
  start-page: 38
  year: 2013
  ident: ref_101
  article-title: Effects of cigarette smoke extract on primary activated T cells
  publication-title: Cell. Immunol.
  doi: 10.1016/j.cellimm.2013.04.005
– volume: 30
  start-page: 1232
  year: 2019
  ident: ref_108
  article-title: ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz116
– volume: 91
  start-page: 47
  year: 2018
  ident: ref_37
  article-title: Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2017.12.016
– volume: 36
  start-page: 21
  year: 2019
  ident: ref_45
  article-title: Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma
  publication-title: Med. Oncol.
  doi: 10.1007/s12032-018-1241-1
– ident: ref_83
  doi: 10.1126/science.aar3593
– volume: 375
  start-page: 1856
  year: 2016
  ident: ref_11
  article-title: Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1602252
– volume: 74
  start-page: 8
  year: 2017
  ident: ref_77
  article-title: Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma
  publication-title: Oral Oncol.
  doi: 10.1016/j.oraloncology.2017.09.002
– volume: 110
  start-page: 1386
  year: 2018
  ident: ref_102
  article-title: Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djy060
– volume: 3
  start-page: e000257
  year: 2018
  ident: ref_57
  article-title: TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma
  publication-title: ESMO Open
  doi: 10.1136/esmoopen-2017-000257
– volume: 41
  start-page: 2676
  year: 2019
  ident: ref_119
  article-title: The change in circulating tumor cells before and during concurrent chemoradiotherapy is associated with survival in patients with locally advanced head and neck cancer
  publication-title: Head Neck
  doi: 10.1002/hed.25744
– volume: 35
  start-page: 1339
  year: 2013
  ident: ref_24
  article-title: Prognostic impact of human papillomavirus status, survivin, and epidermal growth factor receptor expression on survival in patients treated with radiochemotherapy for very advanced nonresectable oropharyngeal cancer
  publication-title: Head Neck
  doi: 10.1002/hed.23126
– volume: 23
  start-page: 5213
  year: 2003
  ident: ref_38
  article-title: CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma
  publication-title: Anticancer Res.
– volume: 357
  start-page: 409
  year: 2017
  ident: ref_104
  article-title: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
  publication-title: Science
  doi: 10.1126/science.aan6733
– volume: 8
  start-page: 2592
  year: 2018
  ident: ref_125
  article-title: Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-018-19245-w
– volume: 11
  start-page: 1160
  year: 2005
  ident: ref_30
  article-title: Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.1160.11.3
– volume: 125
  start-page: 2046
  year: 2015
  ident: ref_95
  article-title: TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI80445
– volume: 109
  start-page: 154
  year: 2019
  ident: ref_50
  article-title: Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: Results from a phase I/II expansion cohort
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2018.12.029
– volume: 27
  start-page: 259
  year: 2018
  ident: ref_47
  article-title: Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma
  publication-title: Surg. Oncol.
  doi: 10.1016/j.suronc.2018.04.007
– volume: 378
  start-page: 2093
  year: 2018
  ident: ref_81
  article-title: Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1801946
– ident: ref_132
  doi: 10.1186/1471-2180-12-144
– ident: ref_39
  doi: 10.1038/s41416-020-0984-6
– ident: ref_121
  doi: 10.1111/jop.13075
– volume: 109
  start-page: 2629
  year: 2013
  ident: ref_60
  article-title: Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2013.645
– volume: 351
  start-page: 1463
  year: 2016
  ident: ref_79
  article-title: Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
  publication-title: Science
  doi: 10.1126/science.aaf1490
– volume: 41
  start-page: 652
  year: 2020
  ident: ref_139
  article-title: Organoid Models of Tumor Immunology
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2020.06.010
– volume: 74
  start-page: 83
  year: 2017
  ident: ref_111
  article-title: Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs)
  publication-title: Oral Oncol.
  doi: 10.1016/j.oraloncology.2017.09.012
– volume: 77
  start-page: CT022
  year: 2017
  ident: ref_135
  article-title: Abstract CT022: Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.AM2017-CT022
– volume: 3
  start-page: 761
  year: 2013
  ident: ref_56
  article-title: Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-13-0103
– volume: 34
  start-page: 3838
  year: 2016
  ident: ref_72
  article-title: Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2016.68.1478
– volume: 8
  start-page: 1535293
  year: 2019
  ident: ref_69
  article-title: Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1535293
– volume: 4
  start-page: e965570
  year: 2015
  ident: ref_67
  article-title: Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma
  publication-title: Oncoimmunology
  doi: 10.4161/21624011.2014.965570
– ident: ref_142
  doi: 10.1001/jamaoncol.2019.2311
– ident: ref_84
  doi: 10.1172/jci.insight.98811
– volume: 6
  start-page: 128
  year: 2018
  ident: ref_15
  article-title: A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-018-0442-7
– volume: 31
  start-page: 1228
  year: 2009
  ident: ref_133
  article-title: Exploring the link between microorganisms and oral cancer: A systematic review of the literature
  publication-title: Head Neck
  doi: 10.1002/hed.21140
– volume: 80
  start-page: 104
  year: 2018
  ident: ref_107
  article-title: Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma
  publication-title: Oral Oncol.
  doi: 10.1016/j.oraloncology.2018.04.001
– volume: 15
  start-page: 249
  year: 2005
  ident: ref_33
  article-title: Bcl-2 as prognostic factor in head and neck squamous cell carcinoma
  publication-title: Oncol. Res.
  doi: 10.3727/096504005776404599
– volume: 243
  start-page: 213
  year: 2018
  ident: ref_18
  article-title: Biomarker definitions and their applications
  publication-title: Exp. Biol. Med.
  doi: 10.1177/1535370217750088
– volume: 9
  start-page: 1084
  year: 2019
  ident: ref_66
  article-title: Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2019.01084
– volume: 6
  start-page: 36956
  year: 2016
  ident: ref_70
  article-title: PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
  publication-title: Sci. Rep.
  doi: 10.1038/srep36956
– volume: 2
  start-page: 261
  year: 1996
  ident: ref_32
  article-title: bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy
  publication-title: Clin. Cancer Res.
– volume: 82
  start-page: 104
  year: 2018
  ident: ref_90
  article-title: Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma
  publication-title: Hum. Pathol.
  doi: 10.1016/j.humpath.2018.07.012
– volume: 2
  start-page: 719
  year: 2018
  ident: ref_144
  article-title: Artificial intelligence in healthcare
  publication-title: Nat. Biomed. Eng.
  doi: 10.1038/s41551-018-0305-z
– volume: 47
  start-page: 52
  year: 2016
  ident: ref_58
  article-title: PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
  publication-title: Hum. Pathol.
  doi: 10.1016/j.humpath.2015.09.003
– volume: 17
  start-page: 956
  year: 2016
  ident: ref_100
  article-title: Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(16)30066-3
– volume: 16
  start-page: 563
  year: 2019
  ident: ref_16
  article-title: Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-019-0218-0
– volume: 6
  start-page: 31726
  year: 2016
  ident: ref_124
  article-title: Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
  publication-title: Sci. Rep.
  doi: 10.1038/srep31726
– volume: 24
  start-page: 134
  year: 2017
  ident: ref_98
  article-title: Gene-expression profiling to predict responsiveness to immunotherapy
  publication-title: Cancer Gene Ther.
  doi: 10.1038/cgt.2016.63
– volume: 25
  start-page: e209
  year: 2018
  ident: ref_65
  article-title: Harmonization of PD-L1 testing in oncology: A Canadian pathology perspective
  publication-title: Curr. Oncol.
  doi: 10.3747/co.25.4031
– volume: 12
  start-page: 252
  year: 2012
  ident: ref_43
  article-title: The blockade of immune checkpoints in cancer immunotherapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3239
– volume: 31
  start-page: 1630
  year: 2018
  ident: ref_63
  article-title: Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms
  publication-title: Mod. Pathol.
  doi: 10.1038/s41379-018-0071-1
– volume: 100
  start-page: 261
  year: 2008
  ident: ref_29
  article-title: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djn011
– volume: 11
  start-page: 1
  year: 2014
  ident: ref_127
  article-title: Gut microbiota: Anti-cancer therapies affected by gut microbiota
  publication-title: Nat. Rev. Gastroenterol. Hepatol.
  doi: 10.1038/nrgastro.2013.238
– volume: 28
  start-page: 1923
  year: 2017
  ident: ref_120
  article-title: Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx206
– ident: ref_55
  doi: 10.1038/nature14129
– volume: 313
  start-page: 1960
  year: 2006
  ident: ref_88
  article-title: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
  publication-title: Science
  doi: 10.1126/science.1129139
– volume: 104
  start-page: 104638
  year: 2020
  ident: ref_114
  article-title: Clinicopathological and prognostic significance of circulating tumor cells in head and neck squamous cell carcinoma: A systematic review and meta-analysis
  publication-title: Oral Oncol.
  doi: 10.1016/j.oraloncology.2020.104638
– volume: 20
  start-page: 1230
  year: 2011
  ident: ref_25
  article-title: Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma
  publication-title: Cancer Epidemiol. Biomark. Prev.
  doi: 10.1158/1055-9965.EPI-10-1262
– volume: 9
  start-page: 13404
  year: 2019
  ident: ref_68
  article-title: HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-019-49771-0
– volume: 35
  start-page: 1542
  year: 2017
  ident: ref_73
  article-title: Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2016.70.1524
– ident: ref_122
  doi: 10.3390/cancers11040540
– volume: 6
  start-page: 3177
  year: 2000
  ident: ref_36
  article-title: EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck
  publication-title: Clin. Cancer Res.
– volume: 81
  start-page: 45
  year: 2018
  ident: ref_54
  article-title: Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
  publication-title: Oral Oncol.
  doi: 10.1016/j.oraloncology.2018.04.008
– volume: 30
  start-page: 57
  year: 2019
  ident: ref_42
  article-title: Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdy507
– volume: 7
  start-page: 9934
  year: 2017
  ident: ref_134
  article-title: Microbial Communities Associated with Primary and Metastatic Head and Neck Squamous Cell Carcinoma—A High Fusobacterial and Low Streptococcal Signature
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-09786-x
– volume: 30
  start-page: 998
  year: 2019
  ident: ref_143
  article-title: Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz108
– volume: 18
  start-page: 1104
  year: 2017
  ident: ref_12
  article-title: Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): Health-related quality-of-life results from a randomised, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30421-7
– volume: 7
  start-page: 184
  year: 2019
  ident: ref_62
  article-title: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-019-0662-5
– volume: 17
  start-page: 271
  year: 2017
  ident: ref_126
  article-title: Microbiota: A key orchestrator of cancer therapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2017.13
– volume: 1
  start-page: e89829
  year: 2016
  ident: ref_71
  article-title: The head and neck cancer immune landscape and its immunotherapeutic implications
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.89829
– volume: 452
  start-page: 548
  year: 2008
  ident: ref_19
  article-title: The cancer biomarker problem
  publication-title: Nature
  doi: 10.1038/nature06913
– volume: 7
  start-page: 1833
  year: 2014
  ident: ref_75
  article-title: APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2014.05.012
– volume: 43
  start-page: 1525
  year: 2020
  ident: ref_115
  article-title: Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma
  publication-title: Oncol. Rep.
– volume: 2
  start-page: 15
  year: 2016
  ident: ref_48
  article-title: PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2015.4685
– volume: 7
  start-page: 261
  year: 2019
  ident: ref_86
  article-title: Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8(+) T cells
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-019-0726-6
– volume: 121
  start-page: 979
  year: 2019
  ident: ref_140
  article-title: Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-019-0616-1
– volume: 22
  start-page: 2908
  year: 2016
  ident: ref_106
  article-title: Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-2412
– volume: 359
  start-page: 1116
  year: 2008
  ident: ref_5
  article-title: Platinum-based chemotherapy plus cetuximab in head and neck cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0802656
– volume: 348
  start-page: 56
  year: 2015
  ident: ref_13
  article-title: The future of immune checkpoint therapy
  publication-title: Science
  doi: 10.1126/science.aaa8172
– volume: 553
  start-page: 91
  year: 2018
  ident: ref_44
  article-title: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
  publication-title: Nature
  doi: 10.1038/nature25015
– volume: 120
  start-page: 108
  year: 2018
  ident: ref_123
  article-title: PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2018.04.001
– volume: 18
  start-page: 87
  year: 2018
  ident: ref_128
  article-title: Cancer immunotherapy in 2017: The breakthrough of the microbiota
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri.2018.4
– volume: 29
  start-page: 2247
  year: 2018
  ident: ref_74
  article-title: Safety and clinical activity of atezolizumab in head and neck cancer: Results from a phase I trial
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdy411
– volume: 96
  start-page: 140
  year: 2019
  ident: ref_78
  article-title: APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma
  publication-title: Oral Oncol.
  doi: 10.1016/j.oraloncology.2019.07.020
– volume: 175
  start-page: 1972
  year: 2018
  ident: ref_138
  article-title: Organoid Modeling of the Tumor Immune Microenvironment
  publication-title: Cell
  doi: 10.1016/j.cell.2018.11.021
– volume: 109
  start-page: 2096
  year: 2013
  ident: ref_34
  article-title: ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: Results from a randomised, phase II trial
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2013.576
– volume: 8
  start-page: 44418
  year: 2017
  ident: ref_91
  article-title: Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.17901
– volume: 37
  start-page: 6002
  year: 2019
  ident: ref_6
  article-title: TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2019.37.15_suppl.6002
– volume: 1
  start-page: 873
  year: 2020
  ident: ref_113
  article-title: Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-020-0096-5
– volume: 359
  start-page: 97
  year: 2018
  ident: ref_130
  article-title: Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
  publication-title: Science
  doi: 10.1126/science.aan4236
– volume: 125
  start-page: 3208
  year: 2019
  ident: ref_97
  article-title: Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial
  publication-title: Cancer
  doi: 10.1002/cncr.32190
– volume: 24
  start-page: 4170
  year: 2006
  ident: ref_22
  article-title: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2006.07.2587
– volume: 378
  start-page: 2078
  year: 2018
  ident: ref_10
  article-title: Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1801005
– volume: 375
  start-page: 1823
  year: 2016
  ident: ref_52
  article-title: Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1606774
– volume: 8
  start-page: 1069
  year: 2018
  ident: ref_7
  article-title: Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-0367
– volume: 77
  start-page: 3540
  year: 2017
  ident: ref_99
  article-title: Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-3556
– volume: 118
  start-page: 9
  year: 2018
  ident: ref_96
  article-title: Mechanisms of resistance to immune checkpoint inhibitors
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2017.434
– volume: 49
  start-page: 1089
  year: 2013
  ident: ref_103
  article-title: Promising systemic immunotherapies in head and neck squamous cell carcinoma
  publication-title: Oral Oncol.
  doi: 10.1016/j.oraloncology.2013.09.009
– volume: 21
  start-page: 2635
  year: 2015
  ident: ref_89
  article-title: Stromal CD8+ T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-14-1905
– volume: 8
  start-page: 52889
  year: 2017
  ident: ref_46
  article-title: PD-L1: A novel prognostic biomarker in head and neck squamous cell carcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.17547
– volume: 23
  start-page: 4938
  year: 2017
  ident: ref_64
  article-title: PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-1821
SSID ssj0023259
Score 2.3714466
SecondaryResourceType review_article
Snippet Recurrent locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) is associated with dismal prognosis because of its highly invasive...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 7621
SubjectTerms Animals
Biomarkers
Biomarkers, Tumor - genetics
Biomarkers, Tumor - immunology
Biomarkers, Tumor - metabolism
Cancer therapies
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - immunology
Chemotherapy
Clinical medicine
Clinical trials
Epidermal growth factor
Gene expression
Head & neck cancer
Head and Neck Neoplasms - drug therapy
Head and Neck Neoplasms - genetics
Head and Neck Neoplasms - immunology
Human papillomavirus
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Ligands
Medical prognosis
Metastasis
Mutation Accumulation
Pharmacodynamics
Practice Guidelines as Topic
Regulatory approval
Response rates
Review
T-Lymphocytes - immunology
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwELZ4CIlL1fLcllaDVE7IIk87OVXVqmhBAqEC0t4iJ7G1gax3YZdDf0z_a2cSZ2Gp4BQpmSSWZ8aez_48w9h3X8s4UFrxMjGSR2mR89wzJTeCcpWEofEa8vjFpRjcRufDeOgW3GaOVtmNic1AXU4KWiM_QSCTiBCD9eTH9IFT1SjaXXUlNFbZOqUuI0qXHD4DLhInwIVzEBdxKlrie4gw_6S6G89w1EYUH_jLU9J_ceZruuSL-ef0I_vgAkf42Wr6E1vRdotttKUk_2yzvy2ZrulnmBjA0A6NvdZwRgdANKDgmJg4jzPAMLW72x_p4n46qewczuyoyiuqvQOVhQGqHpQt4RIF4PrhSdESAfR1XUOfyg9Z_BzcdCx1euU3hpzQcHPAJRut4cqdwdpht6e_bvoD7kov8CLygzmPTSyK3JMyLyKJF_Rs1GoQeOjeuTFJGmlfUplyT2PEIVWplNEyKv3E6DhWfrjL1uzE6n0GCMAQ1PmpzI2MhJLKhAEKUGIxXZap6LHjrvezwuUlp_IYdYb4hHSVvdRVjx0tpKdtPo435A46RWbOK2fZsw312OHiMfoTbZIoq7Ejs6DZ6BWJjw3ba_W--FGIA6JAjNVjcskiFgKUq3v5ia1GTc5uhGXEKPv8frO-sM2A8DwxZuIDtjZ_fNJfMeiZ598ay_4HDHcC-A
  priority: 102
  providerName: ProQuest
Title Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice
URI https://www.ncbi.nlm.nih.gov/pubmed/33076306
https://www.proquest.com/docview/2548632598
https://www.proquest.com/docview/2452506816
https://pubmed.ncbi.nlm.nih.gov/PMC7589088
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Nb9NAEB2VVqBeKj5LoESDBCdksB2v1z4gBFFDitSoKo2Um7W2dxWDu2mTVGp_DP-VGX8ppfQSS_HYjnZmvPOyb-cBvPO0FL7SyskjI50gzlIndU3umJB7lQwGxq3I48eTcDwNfszEbAtatdFmAFf_hXasJzVdlh-vL2--UMJ_ZsRJkP1T8et8RW9gQuS8o3yH5iTJKXocdOsJVDaIuKa937liFx4Rpqc0Y9GjzbnpTsH5L29yYyIaPYa9poLEr7XLn8CWtk_hYa0pefMM_tSsumrAcWGQajyK-lLjEe8E0UiG50zJWa6Q6tX22-FcZ78vFoVd45GdF2nBIjxYWBxTDKCyOU7IAH9eXin-rwCHuixxyDpElm6HZy1dnS85pdoTK5IONl1HSzxpNmM9h-no8Gw4dhoNBicLPH_tCCPCLHWlTLNA0oFSnNzr-y7leWpMFAfak6xX7moqPaTKlTJaBrkXGS2E8gYvYNsurH4JSEiM0J0Xy9TIIFRSmYFPBtxhTOd5HPbgQzv6SdY0KGedjDIhoMJuSzbd1oP3nfVF3ZjjHruD1pFJG10JoeIo5JiIevC2O02JxaslymoayMSvVnzDyKMftl_7vXtQGzA9kLciojPgpt23z9hiXjXvJnzG1LJX997zNez6jOmZNSMOYHu9vNJvqPBZp314IGeSPqPR9z7sfDucnJz2eSoS_Sra_wL34Ae5
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VIgQXxJuUAoNET8iqn7v2ASEUqBLaRghSKTeztncVU3eTNqlQfwx_gd_IjB9pA4JbT5biib3yzM7Mt_vtDMBrT8vIV1o5RWykEyZ55mSuKRwjuFZJEBi3Jo8fjsTgKPw0iSYb8Ks7C8O0ys4n1o66mOW8Rr5LQCYWASXr8bv5qcNdo3h3tWuh0ZjFvr74QZBt8Xb4gfS74_t7H8f9gdN2FXDy0POXTmQikWeulFkeSrqQ0dKAfd8ly82MiZNQe5I7cLuagqlUhVJGy7DwYqOjSHkBPfcG3KTA6_KMkpNLgMfDY4BHMc8RUSIaon0QJO5u-f1kQVHCJd_jrYfAv_LaP-mZV-Ld3j242yaq-L6xrPuwoe0DuNW0rrx4CD8b8l6tV5wZpFSSJlelccgHTjSS4Akzf84WSGlx92t_qvPj-ay0SxzaaZmV3OsHS4sDMjVUtsARCeDX03PFSxLY11WFfW53ZOlxOO5Y8fyXL5TiYs0Fwra4aYWf2zNfj-DoWpTyGDbtzOqngAT4CER6icyMDIWSygQ-CXAhM10UiejBm-7rp3lbB53bcVQp4SHWVXpVVz3YWUnPm_of_5Db7hSZtl5gkV7abA9erW7T_OVNGWU1fcjUrzeWRezRwJ40el-9KCAHLAjT9UCuWcRKgGuDr9-x5bSuEU4wkBlsW_8f1ku4PRgfHqQHw9H-M7jj81oCs3Wibdhcnp3r55RwLbMXtZUjfLvuafUbJrc-mQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VIhAXxJtAgUGiJ2TFz137gBBKiRIKUQWtlJtZ27uKwd2kTSrUH8Mf4dcx40fagODWkyV7bK923rvfzgC88rSMfKWVU8RGOmGSZ07mmsIxgmuVBIFxa_D4p4kYHYUfptF0C351Z2EYVtnZxNpQF_Oc18j7lMjEIqBgPe6bFhZxsDd8uzhxuIMU77R27TQaEdnX5z8ofVu-Ge8Rr3d9f_j-cDBy2g4DTh56_sqJTCTyzJUyy0NJFxJgGrzvuyTFmTFxEmpPcjduV5NjlapQymgZFl5sdBQpL6DvXoPrMog81jE5vUj2eKic7JH_c0SUiAZ0HwSJ2y-_HS_JY7hkh7xNd_hXjPsnVPOS7xvegdtt0IrvGim7C1va3oMbTRvL8_vwswHy1TzGuUEKK0nRKo1jPnyikQiPGQV0ukQKkbu7g5nOvy_mpV3h2M7KrOS-P1haHJHYobIFTogAv5ycKV6ewIGuKhxw6yNLn8PDDiHPr3ymcBdrXBC2hU4rPGjPfz2AoythykPYtnOrHwNS8kcJpZfIzMhQKKlM4BMBFzXTRZGIHrzuZj_N25ro3JqjSik3Yl6ll3nVg9019aKpBfIPup2OkWlrEZbphfz24OX6Mekyb9Aoq2kiU7_eZBaxRwN71PB9_aOAjLGg_K4HckMi1gRcJ3zziS1ndb1wSgkZzfbk_8N6ATdJodKP48n-U7jl87ICA3eiHdhenZ7pZxR7rbLntZAjfL1qrfoN3PNCzw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Exploration+of+Feasible+Immune+Biomarkers+for+Immune+Checkpoint+Inhibitors+in+Head+and+Neck+Squamous+Cell+Carcinoma+Treatment+in+Real+World+Clinical+Practice&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Wang%2C+Hui-Ching&rft.au=Yeh%2C+Tsung-Jang&rft.au=Chan%2C+Leong-Perng&rft.au=Hsu%2C+Chin-Mu&rft.date=2020-10-15&rft.eissn=1422-0067&rft.volume=21&rft.issue=20&rft_id=info:doi/10.3390%2Fijms21207621&rft_id=info%3Apmid%2F33076306&rft.externalDocID=33076306
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon